BackTable / Urology / Topic / Specialization
Learn more on the BackTable Urology Podcast
BackTable is a knowledge resource for physicians by physicians. Get practical advice on Urologic Oncology and how to build your practice by listening to the BackTable Urology Podcast, reading exclusing BackTable Articles, and following the work of our Contributors.
Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs. Follow the button below to claim your credits on CMEfy.
Stay Up To Date
Urologic Oncology Podcasts
Listen to leading physicians discuss urologic oncology on the BackTable Urology Podcast. Get tips, tricks, and expert guidance from your peers and level up your practice.
On this episode of BackTable Urology, Dr. Aditya Bagrodia, Dr. Daniel Costa (UT Southwestern), and Dr. Xiaosong Meng (UT Southwestern) discuss patient selection and procedure for TULSA-PRO, a new transurethral ultrasound ablation system that incorporates real-time MR imaging, as a focal treatment option for prostate cancer.
In this episode of BackTable Urology, Dr. Aditya Bagrodia speaks with urologist Dr. Anne Schuckman from the University of Southern California about advantages and advice for blue light cystoscopy, a procedure performed to identify bladder tumors during transurethral resection of bladder tumor (TURBT).
Dr. Philippe Spiess from Moffitt Cancer Center discusses surgical and medical management of penile cancer. Listen now to hear more about punch biopsy techniques, surgical resection and lymph node dissection techniques, growing role of topical chemotherapy, importance of multidisciplinary tumor boards.
Urologic Oncology Articles
Read our exclusive BackTable Urology Articles for quick insights on urologic oncology, provided by physicians for physicians.
Proper patient selection and preparation are crucial for success with TULSA prostate treatment. Our urology and radiology panel explain TULSA patient selection, absolute and relative contraindications to TULSA, how to prep patients for TULSA prostate treatment, potential side effects of TULSA, and expected outcomes.
BCG-unresponsive bladder cancer has distinct criteria for diagnosis and management. Official FDA diagnosis requires the development or recurrence of a high-grade bladder tumor after a patient has received adequate BCG therapy. Treatment duration varies based on whether an induction or maintenance course is indicated.
Disclaimer: The Materials available on https://www.BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.